

**WEST Search History****Hide Items****Restore****Clear****Cancel**

DATE: Monday, September 12, 2005

Hide?	Set Name	Query	Hit Count
	DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR		
<input type="checkbox"/>	L1	patti.in. or foster.in. or hook.in.	16803
<input type="checkbox"/>	L2	L1 and staphy\$	150
<input type="checkbox"/>	L3	L2 and (sdr or serine or donar or donor)	59
<input type="checkbox"/>	L4	L3 and (aureus and epidermidis).clm.	5

END OF SEARCH HISTORY

updated  
search  
9/12/05

100  
Recommended  
prior  
to  
search  
pull out  
of record

☐ 1. 20040101919. 15 Sep 03. 27 May 04. Bioinformatic method for identifying surface-anchored proteins from gram-positive bacteria and proteins obtained thereby. Hook, Magnus, et al. 435/7.32; G01N033/554 G01N033/569.

☐ 2. 20030186275. 18 Mar 03. 02 Oct 03. Antigenic polypeptides. Foster, Simon, et al. 435/6; 435/252.3 435/320.1 435/325 435/69.1 530/350 536/23.5 C12Q001/68 C07H021/04 C12P021/02 C12N001/21 C12N005/06 C07K014/195 C12N015/74 C12P021/06 C12N001/20 C12N015/00 C12N015/09 C12N015/63 C12N015/70 C12N005/00 C12N005/02 C07K001/00 C07K014/00 C07K017/00.

☐ 3. 20020159997. 07 Mar 02. 31 Oct 02. Staphylococcal immunotherapeutics via donor selection and donor stimulation. Patti, Joseph M., et al. 424/142.1; 530/388.15 A61K039/395 C07K016/40.

☐ 4. 6703025. 31 Aug 99; 09 Mar 04. Multicomponent vaccines. Patti, Joseph M., et al. 424/243.1; 424/184.1 424/190.1 424/193.1 424/203.1 424/234.1 424/244.1 530/350. A61K039/085.

☐ 5. 6692739. 31 Aug 99; 17 Feb 04. Staphylococcal immunotherapeutics via donor selection and donor stimulation. Patti, Joseph M., et al. 424/130.1; 424/137.1 424/150.1 424/185.1 530/387.1 530/387.5 530/388.2 530/388.4. A61K039/395.

Generate Collection

Print

Term	Documents
AUREUS	22704
AUREU	18
EPIDERMIDIS	3965
EPIDERMIDI	2
(3 AND ((EPIDERMIDIS AND AUREUS).CLM.)).PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD.	5
(L3 AND (AUREUS AND EPIDERMIDIS).CLM.)).PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD.	5

[Prev Page](#)   [Next Page](#)   [Go to Doc#](#)

US-PAT-NO: 6703025

DOCUMENT-IDENTIFIER: US 6703025 B1

TITLE: Multicomponent vaccines

DATE-ISSUED: March 9, 2004

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
<u>Patti</u> ; Joseph M.	Cumming	GA		
<u>Foster</u> ; Timothy J.	Dublin			IE
<u>Hook</u> ; Magnus	Houston	TX		

US-CL-CURRENT: 424/243.1; 424/184.1, 424/190.1, 424/193.1, 424/203.1, 424/234.1, 424/244.1, 530/350

## CLAIMS:

What is claimed is:

1. A multicomponent vaccine consisting essentially of immunologically effective amounts of the collagen binding domain of a Staphylococcal collagen binding protein, and the fibrinogen binding domain of a Staphylococcal fibrinogen binding protein, and a pharmaceutically acceptable carrier or excipient.
2. A vaccine according to claim 1 further comprising the fibronectin binding domain of a Staphylococcal fibronectin binding protein.
3. A vaccine according to claim 1 wherein the staphylococcal organisms are Staphylococcus aureus.
4. A vaccine according to claim 3, wherein the Staphylococcus aureus binding proteins are selected from the group consisting of the collagen binding adhesin CNA, clumping factor A (ClfA) and clumping factor B (ClfB).
5. A vaccine according to claim 1 further comprising an SdrH protein from Staphylococcus epidermidis.
6. A vaccine according to claim 1 wherein the collagen binding protein is selected from the group consisting of the collagen binding adhesin CNA and the collagen binding adhesin subdomain M55.
7. A vaccine according to claim 1 wherein the fibrinogen binding protein is selected from the group consisting of clumping factor A (ClfA) and clumping factor B (ClfB).
8. A vaccine according to claim 2 wherein the fibronectin binding protein is selected from the group consisting of fibronectin binding protein A (FnBP-A) and fibronectin binding protein B (FnBP-B).

US-PAT-NO: 6692739

DOCUMENT-IDENTIFIER: US 6692739 B1

TITLE: Staphylococcal immunotherapeutics via donor selection and donor stimulation

DATE-ISSUED: February 17, 2004

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
<u>Patti</u> ; Joseph M.	Cumming	GA		
<u>Foster</u> ; Timothy J.	Dublin			IE
<u>Hook</u> ; Magnus	Houston	TX		

US-CL-CURRENT: 424/130.1; 424/137.1, 424/150.1, 424/185.1, 530/387.1, 530/387.5, 530/388.2, 530/388.4

## CLAIMS:

What is claimed is:

1. A selected purified human donor immunoglobulin composition comprising an antibody titer to an S. aureus serine-aspartate repeat (Sdr) protein in combination with an antibody titer to an S. epidermidis serine-aspartate repeat (Sdr) protein wherein both antibody titers are higher than that found in pooled intravenous immunoglobulin obtained from unselected human donors, said composition obtained by a method comprising obtaining blood or plasma samples from human donors, screening said samples so as to select those samples having an antibody titer to an S. aureus Sdr protein and an antibody titer to an S. epidermidis Sdr protein that are both in an amount that is higher than that found in pooled intravenous immunoglobulin obtained from unselected donors, recovering blood or plasma from the selected high-titer donors, and treating the donor blood plasma to obtain immunoglobulin in a purified state having an antibody titer to an S. aureus Sdr protein and an antibody titer to an S. epidermidis Sdr protein that are both in an amount which is higher than that found in pooled intravenous immunoglobulin obtained from unselected human donors.

2. The donor immunoglobulin composition of claim 1 wherein the S. aureus Sdr protein is selected from the group consisting of clumping factor A (ClfA), clumping factor B (ClfB), SdrC, SdrD, and SdrE.

3. The donor immunoglobulin composition of claim 1 wherein the S. epidermidis Sdr protein is selected from the group consisting of SdrF, SdrG and SdrH.

4. The donor immunoglobulin composition of claim 1 wherein the S. aureus Sdr protein is clumping factor A (ClfA).

5. The donor immunoglobulin composition of claim 1 wherein the S. aureus Sdr protein is clumping factor B (ClfB).

6. The donor immunoglobulin composition of claim 1 wherein the S. aureus Sdr protein is SdrC.

7. The donor immunoglobulin composition of claim 1 wherein the S. aureus Sdr protein is SdrD.
8. The donor immunoglobulin composition of claim 1 wherein the S. epidermidis Sdr protein is SdrE.
9. The donor immunoglobulin composition of claim 1 wherein the S. epidermidis Sdr protein is SdrF.
10. The donor immunoglobulin composition of claim 1 wherein the S. epidermidis Sdr protein is SdrG.
11. The donor immunoglobulin composition of claim 1 wherein the S. epidermidis Sdr protein is SdrH.
12. The donor immunoglobulin composition of claim 1 wherein the composition has an antibody titer to an S. aureus Sdr protein in an amount that is 2-fold or greater than that found in pooled intravenous immunoglobulin obtained from unselected donors.
13. The donor immunoglobulin composition of claim 1 wherein the composition has a total antibody titer to an S. aureus Sdr protein that is greater than 0.2 Units/mg/IgG.
14. A purified human donor immunoglobulin composition comprising an antibody titer to an S. aureus serine-aspartate repeat (Sdr) protein combination with an antibody titer to an S. epidermidis serine-aspartate repeat (Sdr) protein wherein both antibody titers are higher than that found in pooled intravenous immunoglobulin obtained from unselected human donors obtained by a method comprising administering an S. aureus Sdr protein to a human host donor in an amount sufficient to induce an antibody titer to the S. aureus Sdr protein that is higher than that found in pooled intravenous immunoglobulin obtained from unselected donors, and administering an S. epidermidis Sdr protein to a human host donor in an amount sufficient to induce an antibody titer to the S. epidermidis Sdr protein that is higher than that found in pooled intravenous immunoglobulin obtained from unselected donors, recovering blood or plasma samples from the induced donors, and treating the donor blood or plasma to obtain immunoglobulin in a purified state having antibody titer to an S. aureus Sdr protein and an antibody titer to an S. epidermidis Sdr protein that are both in an amount which is higher than that found in pooled intravenous immunoglobulin obtained from unselected human donors.
15. The donor immunoglobulin composition of claim 14 wherein the S. aureus Sdr protein is selected from the group consisting of clumping factor A (ClfA), clumping factor B (ClfB), SdrC, SdrD, and SdrE.
16. The donor immunoglobulin composition of claim 14 wherein the S. epidermidis Sdr protein is selected from the group consisting of SdrF, SdrG and SdrH.
17. The donor immunoglobulin composition of claim 14 wherein the S. aureus Sdr protein is clumping factor A (ClfA).
18. The donor immunoglobulin composition of claim 14 wherein the S. aureus Sdr protein is clumping factor B (ClfB).

19. The donor immunoglobulin composition of claim 14 wherein the S. aureus Sdr protein is SdrC.
20. The donor immunoglobulin composition of claim 14 wherein the S. aureus Sdr protein is SdrD.
21. The donor immunoglobulin composition of claim 14 wherein the S. aureus Sdr protein is SdrE.
22. The donor immunoglobulin composition of claim 14 wherein the S. epidermidis Sdr protein is SdrF.
23. The donor immunoglobulin composition of claim 14 wherein the S. epidermidis Sdr protein is SdrG.
24. The donor immunoglobulin composition of claim 14 wherein the S. epidermidis Sdr protein is SdrH.
25. The donor immunoglobulin composition of claim 14 wherein the composition has an antibody titer to an S. aureus Sdr protein in an amount that is 2-fold or greater than that found in pooled intravenous immunoglobulin obtain from unselected donors.
26. The donor immunoglobulin composition of claim 14 wherein the composition has a total antibody titer to an S. aureus Sdr protein that is greater than 0.2 Units/mg/IgG.